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Cognitive reactivityBackground: Recent insights into the role of the human microbiota in cognitive and affective functioning
have led to the hypothesis that probiotic supplementation may act as an adjuvant strategy to ameliorate
or prevent depression. Objective: Heightened cognitive reactivity to normal, transient changes in sad
mood is an established marker of vulnerability to depression and is considered an important target for
interventions. The present study aimed to test if a multispecies probiotic containing Biﬁdobacterium biﬁ-
dumW23, Biﬁdobacterium lactisW52, Lactobacillus acidophilusW37, Lactobacillus brevisW63, Lactobacillus
casei W56, Lactobacillus salivarius W24, and Lactococcus lactis (W19 and W58) may reduce cognitive
reactivity in non-depressed individuals. Design: In a triple-blind, placebo-controlled, randomized, pre-
and post-intervention assessment design, 20 healthy participants without current mood disorder
received a 4-week probiotic food-supplement intervention with the multispecies probiotics, while 20
control participants received an inert placebo for the same period. In the pre- and post-intervention
assessment, cognitive reactivity to sad mood was assessed using the revised Leiden index of depression
sensitivity scale. Results: Compared to participants who received the placebo intervention, participants
who received the 4-week multispecies probiotics intervention showed a signiﬁcantly reduced overall
cognitive reactivity to sad mood, which was largely accounted for by reduced rumination and aggressive
thoughts. Conclusion: These results provide the ﬁrst evidence that the intake of probiotics may help
reduce negative thoughts associated with sad mood. Probiotics supplementation warrants further
research as a potential preventive strategy for depression.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The intestine and the brain are intimately connected via the
brain-gut axis, which involves bidirectional communication via
neural, endocrine and immune pathways (Grossman, 1979;
Grenham et al., 2011; Mayer, 2011; Mayer et al., 2014). In recent
years it has become increasingly evident that this communicationalso involves interactions with the intestinal microbiota, which
release immune activating and other signaling molecules that
may play an important role in regulating the brain and subsequent
behavior (Mayer, 2011; Cryan and Dinan, 2012; Foster and McVey
Neufeld, 2013). For example, the microbiota produce neuroactive
substances and their precursors (e.g., tryptophan) which can reach
the brain via endocrine and afferent autonomic pathways
(Desbonnet et al., 2008, 2010). Also, bacterial products, such as
the gram-negative endotoxins, can inﬂuence mood and cognitive
functions via indirect (e.g., immune activation) and direct (e.g.,
Toll-like receptors on glial cells) mechanisms (Lehnardt et al.,
2003; Krabbe et al., 2005; Ait-Belgnaoui et al., 2012; McCusker
and Kelley, 2013).
These novel insights have fuelled the hypothesis that modiﬁca-
tion of microbial ecology, for example by supplements containing
microbial species (probiotics), may be used therapeutically to
modify stress responses and symptoms of anxiety and depression
(Logan and Katzman, 2005; Cryan and O’Mahony, 2011;
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recent, and predominantly involves animal and pre-clinical human
studies, the results appear in support of this hypothesis (Logan and
Katzman, 2005; Cryan and Dinan, 2012; Foster and McVey Neufeld,
2013; Tillisch, 2014; Savignac et al., 2015). For instance, Bravo et al.
(2011) observed a reduction in anxious and depressive behavior
after feeding healthy mice with Lactobacillus rhamnosus JB-1.
Similarly, Desbonnet et al. (2010) observed a reduction in depres-
sive-like behaviors in adult rats after feeding them with
Biﬁdobacterium infantis 35624. This reduction was comparable to
the effects of administering the antidepressant citalopram
(Desbonnet et al., 2010). Probiotic studies in humans are still
scarce, but the available data are promising. For example, Benton
et al. (2006) found in a non-clinical sample that a 3-week interven-
tion with probiotics-containing milk drink (i.e., Lactobacillus casei
Shirota) improved mood scores compared to participants who
received a placebo intervention. Improvement in mood was only
observed for participants who showed elevated symptoms of
depression at baseline. In another pre-clinical study it was demon-
strated that participants who were given a mixture of probiotics
containing Lactobacillus helveticus R0052 and Biﬁdobacterium
longum R0175 showed signiﬁcantly less psychological distress than
matched controls (Messaoudi et al., 2011). Furthermore, Rao et al.
(2009) demonstrated that patients with chronic fatigue syndrome,
which is often comorbid with anxiety disorders, reported signiﬁ-
cantly less anxiety symptoms after ingestion of a daily dose of
L. casei Shirota for 2 months, as compared to a placebo group. On
the basis of these and other results it has been suggested that pro-
biotics may serve as adjuvant or preventive therapy for depression
(for reviews see Logan and Katzman, 2005; Cryan and Dinan, 2012;
Foster and McVey Neufeld, 2013; Tillisch, 2014).
These novel discoveries come at an opportune time. The
increasing incidence of depression is alarming and development
of preventive measures has been identiﬁed as a priority (World
Health Organization, 2012). According to cognitive theories of
depression, cognitive reactivity plays a central role in the develop-
ment, maintenance, and recurrence of depression and therefore is a
relevant target for interventions (Beck, 1967; Kovacs and Beck,
1978; Abramson et al., 1989; Haaga et al., 1991; Scher et al.,
2005; Ingram et al., 2006). Cognitive reactivity refers to the activa-
tion of dysfunctional patterns of thinking that are triggered by sub-
tle changes in mood, such as ruminative (e.g., recurrent thoughts
about possible causes and consequences of one’s distress), aggres-
sive (e.g., to think about hurting others or oneself), hopelessness
(e.g., loss of motivation and expectations about the future), and/
or suicidal thoughts (e.g., to think that one’s death is the only
way to end the suffering). Such dysfunctional cognitive responses
are assumed to stem from latent negative beliefs that become
reactivated during low mood (Beck, 1967).
The degree to which these dysfunctional thoughts are activated
seems to be critical in determining whether sad mood will be a
transient state or will become protracted, increasing the risk of
developing clinical depression (Beck, 1967; Kovacs and Beck,
1978; Abramson et al., 1989; Haaga et al., 1991; Scher et al.,
2005; Ingram et al., 2006). Indeed, cognitive reactivity is consid-
ered one of the most predictive vulnerability markers of depression
(Beck, 1967; Segal et al., 1999, 2006; Moulds et al., 2008). Among
these dysfunctional thought patterns, rumination seems to be par-
ticularly relevant (Nolen-Hoeksema et al., 1993; Kuehner and
Weber, 1999; Nolen-Hoeksema, 2000; Spasojevic and Alloy,
2001; Moulds et al., 2008). For instance, Moulds et al. (2008)
showed that recovered and never-depressed individuals mainly
differ in the degree of activation of ruminative thoughts when
experiencing sad mood. Evidence strongly suggesting a causal role
of cognitive reactivity in depression onset is provided by a recent
study of Kruijt et al. (2013), who showed that higher cognitivereactivity precedes and predicts the episode of depression:
never-depressed individuals with high scores on cognitive reactiv-
ity were more likely to develop a clinical depression during the
subsequent two years, as compared to individuals with lower
scores (see also van der Does, 2005, for a review). These associa-
tions were independent of a range of confounding factors including
baseline mood, life events, and family history of mood disorders
(Kruijt et al., 2013). Thus, interventions targeting cognitive reactiv-
ity may offer a promising approach to prevent and/or to reduce the
incidence of depression-related disorders in the population.
In light of the preceding discussion, the present study aimed to
complement previous ﬁndings by assessing the possible beneﬁcial
effect of probiotics on cognitive reactivity to sad mood, a vulnera-
bility marker for depression. To this end, healthy individuals with-
out any current mood disorder underwent a 4-week intervention
period, during which they were supplied with either probiotics
or an inert placebo. We tested the effect of multispecies probiotics
containing different stains and species of the genera Lactobacillus,
Lactococcus and Biﬁdobacterium (see methods for further details).
These genera have been found to be effective in ameliorating anx-
ious and depressive symptoms (Benton et al., 2006; Rao et al.,
2009; Yamamura et al., 2009; Desbonnet et al., 2010; Bravo
et al., 2011; Messaoudi et al., 2011).
Importantly, studies have shown that multispecies probiotics
(i.e., combining different strains of speciﬁc genera) can have
increased effectiveness through an additive effect of speciﬁc strain
properties such as colonization of different niches, enhanced adhe-
sion and induction of an optimal pH range, as compared to mono-
species supplements (Timmerman et al., 2004; Chapman et al.,
2011). Each bacterial strain of the multispecies probiotics used in
this study has been found to improve epithelial barrier function
both when tested separately and in combination (Van Hemert
and Ormel, 2014). However, some probiotics may compete with
each other in terms of functionality and therefore the assumption
that combinations of different strains may have additive effects
needs veriﬁcation on a preparation by preparation basis.
Before and after the intervention, perceived cognitive reactivity
to transient changes in sad mood was measured by means of the
revised Leiden Index of Depression Sensitivity (LEIDS-r; van der
Does and Williams, 2003), which has been shown to be predictive
of depression in multiple longitudinal studies (van der Does, 2005;
Kruijt et al., 2013). It was hypothesized that the probiotics inter-
vention would lower the activation of negative thoughts that
accompany sad mood, i.e., it would decrease cognitive reactivity
as measured by the LEIDS-r.2. Material and methods
2.1. Participants
Forty non-smoking young adults, with no reported cardiac,
renal, or hepatic conditions, no allergies or intolerance to lactose
or gluten, no prescribed medication or drug use, and who reported
to consume no more than 3–5 alcohol units per week participated
in the study. All participants were screened via a phone interview
by the experiment leader before inclusion. During the phone inter-
view, the Mini International Neuropsychiatric Interview (M.I.N.I.;
Sheehan et al., 1998) was administered too. The M.I.N.I. is a short
structured interview, taking about 15 min, which screens for sev-
eral psychiatric disorders (Sheehan et al., 1998; Colzato et al.,
2008, 2010). Participants with no psychiatric or neurological disor-
ders, no personal or family history of depression or migraine were
considered suitable to take part in the study. Participants were
equally and randomly assigned to receive a 4-week intervention
of either placebo or probiotics. Twenty participants (3 male) with
Table 1
Demographic characteristics for the Placebo and Probiotics groups. Standard
deviations are shown within parentheses.
Placebo Probiotics
N (M:F) 20 (3:17) 20 (5:15)
Age (years) 19.7 (1.7) 20.2 (2.4)
Body Mass Index (BMI) 21.5 (2.0) 22.6 (2.3)
1 Since these tasks were unrelated to the aim of the current study, they are not
rther discussed here. Given that participants performed the two social cognitive
sks after ﬁlling out the questionnaires, we can rule out that participants’ scores
ight have been inﬂuenced by performing these tasks.
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(BMI) of 21.5 (SD = 2.0) were assigned to the placebo condition,
and twenty participants (5 male) with a mean age of 20.2 years
(SD = 2.4) and a mean BMI of 22.6 (SD = 2.2) were assigned to the
probiotics condition (see Table 1). Female participants were not
controlled for the menstrual cycle. No information was provided
about the different types of intervention (probiotics vs. placebo)
or about the hypotheses concerning the outcome of the experi-
ment. All participants believed they were supplied with probiotic
supplementation. When informed about the different conditions
during the debrieﬁng, none of the participants brought up the
deception. Written informed consent was obtained from all partici-
pants and the protocol was approved by the local ethical commit-
tee (Leiden University, Institute for Psychological Research).
2.2. Design and procedure
A blind at three levels (group allocator, participants, outcome
assessor), placebo-controlled, randomized, pre- and post-interven-
tion assessment design was used to investigate the effect of multi-
species probiotic intervention on cognitive reactivity to sad mood,
as well as reported symptoms of depression and anxiety in healthy
young students. Participants received a 4-week food supple-
mentation intervention of either placebo or probiotics. In the pro-
biotics intervention participants were provided with 28 sachets
(one for each day of intervention), each containing 2 g freeze-dried
powder of the probiotic mixture EcologicBarrier (Winclove pro-
biotics, The Netherlands). EcologicBarrier (2.5  109 CFU/g) con-
tains the following bacterial stains: Biﬁdobacterium biﬁdum W23,
Biﬁdobacterium lactis W52, Lactobacillus acidophilus W37,
Lactobacillus brevis W63, L. casei W56, Lactobacillus salivarius
W24, and Lactococcus lactis (W19 and W58). In the placebo inter-
vention, participants were provided with 28 sachets, each contain-
ing 2 g freeze-dried powder of the carrier of the probiotic product:
maize starch and maltodextrins. The placebo was indistinguishable
from the probiotics sachets in color, taste, and smell, but contained
no bacteria. The bacteria in Ecologic Barrier have been identiﬁed by
using 16S rRNA sequencing and the results have been compared
with the bacterial nucleotide database of the National Center for
Biotechnology Information (NCBI). The viability of the probiotic
bacteria was checked both by the producer and by an independent
lab (Institut für Mikroökologie GmbH, Herborn, Germany, special-
ized in microbial analysis, ISO15189 certiﬁcated) by determining
the number of colony forming units. 1 g of the product was mixed
well with 9 ml of a physiological salt solution (0.9% NaCl in ddH2O).
This mixture was tenfold serial diluted in the same physiological
salt solution, and 50 ll of each dilution was plated on Mann
Rogosa Sharpe (MRS) + 0.5% cysteine agar plates. The plates were
incubated anaerobically for 48–72 h at 37 C. The number of
colonies was counted and the total number of colony forming
units was calculated based on the dilution and the number of
colonies. The batch used for the present experiments contained
>2.5  109 CFU/g, whereas the placebo contained <1  104 CFU/g.
Rehydration of freeze-dried lactic acid bacteria in milk, water
and physiological salt solution has been shown to result in
equal survival rates (de Valdez et al., 1985). Stability studies,
whereby the number of colony forming units was determined
every three months, showed that the freeze-dried product is stable
for at least 1.5 years when stored at 25 C with 60% relative
humidity.
At the pre- and post-intervention assessments, participants
ﬁlled out a questionnaire to assess cognitive reactivity to sad mood
and questionnaires that assessed symptoms of depression and
anxiety. E-prime 2.0 software system (Psychology Software Tools,
Inc., Pittsburgh, PA) was used to present the questionnaires and
to collect participants’ responses, which were to be given usingthe computer mouse. After having ﬁlled out the questionnaires,
participants performed two social cognitive tasks tapping into
reactions to fairness (ultimatum game) and interpersonal trust
(trust game) unrelated to the purposes of the present study (data
not reported here).1 In each session, the complete test battery lasted
about 20 min.
At the end of the pre-intervention assessment, participants
were provided with the 28 sachets of powder (containing either
the inert placebo or the multispecies probiotics) for the 4-week
intervention. Participants were instructed, using their own sup-
plies, to dissolve the powder in water or lukewarm milk and to
drink it in the evening before going to bed. Compliance was facili-
tated by reminding the participants via a text message sent by the
experimenter.2.3. Questionnaires
The LEIDS-r (van der Does and Williams, 2003) is a self-report
questionnaire with 34 items that assesses to what extent dysfunc-
tional thoughts are activated when experiencing mild dysphoria
(i.e., it measures cognitive reactivity to sad mood, also referred to
as vulnerability to depression). LEIDS-r scores have been found to
predict depression incidence in multiple longitudinal studies and
to correlate with depression risk factors, such as depression history
(Moulds et al., 2008), genetic markers of depression (Antypa and
van der Does, 2010), and reaction to tryptophan depletion (Booij
and van der Does, 2007). Before answering the items, participants
were asked to take a few minutes to imagine how they would feel
and think if they were to experience a sad mood and then to indi-
cate, on a 5-point Likert scale ranging from 0 (i.e. ‘not at all’) to 4
(‘very strongly’), the extent to which each statement applied to
them. It was emphasized that the statements applied to the situa-
tions when ‘‘it is certainly not a good day, but you don’t feel truly
down or depressed’’. The scale consists of six subscales that mea-
sure vulnerability with respect to:
- Aggression (e.g., When I feel down, I lose my temper more
easily);
- Hopelessness/Suicidality (e.g., When I feel down, I more often
feel hopeless about everything; When I feel sad, I feel more that
people would be better off if I were dead);
- Acceptance/Coping (e.g., When I am sad, I feel more like
myself);
- Control/Perfectionism (e.g., I work harder when I feel down);
- Risk aversion (e.g., When I feel down, I take fewer risks);
- Rumination (e.g., When I feel sad, I more often think about how
my life could have been different).
Hopelessness and Acceptance/Coping both consist of 5 items,
with a maximum score of 20 per subscale, whereas the other scalesfu
ta
m
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LEIDS-r total score is derived by adding up the scores from each
subscale, resulting in total scores ranging from 0 to 136. Internal
consistency (Cronbach’s alpha; a) is 0.89 for the LEIDS total score,
and ranges between 0.62 (Acceptance/Coping) and 0.84 for the
subscales (Hopelessness/Suicidality; Antypa and van der Does,
2010; Williams et al., 2008).
The Beck Depression Inventory II (BDI-II) (Beck et al., 1996) is a
widely used 21-item multiple-choice self-report questionnaire
with high internal consistency (a = .91; Beck et al., 1996), which
assesses the existence and severity of current (past 2 weeks)
depressive symptoms. The study used the Dutch translation vali-
dated by Van der Does (2002b). The BDI–II has been found to be
a valid indicator of depression and show good diagnostic discrim-
ination (Dozois et al., 1998). Participants were presented with
items related to sumptoms of depression and asked to choose,
for each item, the statement that best described how they have
been feeling during the past 2 weeks (including the current day).
Items are rated on a 4-point scale ranging from 0 to 3 in terms of
severity. The total score is calculated by adding-up all items, hence
scores range between 0 and 63 (0–13: minimal depression, 14–19:
mild depression, 20–28: moderate depression and 29–63: severe
depression; van der Does, 2002a).
The Beck Anxiety Inventory (BAI) (Beck et al., 1988) is a 21-item
self-report questionnaire with high internal consistency (a = .90;
Beck and Steer, 1993), which assesses the existence and severity
of anxiety symptoms. A validated Dutch translation was used
(Bouman, 1994). Participants are presented with items describing
common symptoms of anxiety (such as numbness and tingling,
sweating not due to heat, and fear of the worst happening) and
asked to rate, on a 4-point Likert scale (0, not at all, 1, mildly, 2,
moderately, 3, severely), how much they have been bothered by
each symptom over the past week. Total scores are obtained by
summing all items, with values ranging between 0 and 63 (as sug-
gested by Beck and Steer (1993); 0–9: normal anxiety; 10–18:
mild-moderate; 19–29: moderate-severe and 30–63: severe
anxiety).2.4. Statistical analyses
For each questionnaire, the mean scores (total and/or partial)
were calculated and submitted to a repeated measures analysis
of variance (ANOVA) with time (pre- vs. post-intervention) as
within-subjects factor and group (placebo vs. probiotics) as
between-subjects factor. All alpha levels were set at p = .05.
Tukey HSD post hoc tests were performed to clarify mean differ-
ences in case of signiﬁcant interactions.
In addition to standard statistical methods, we calculated
Bayesian (posterior) probabilities associated with the occurrence
of the null [p(H0|D)] and alternative [p(H1|D)] hypotheses, given
the observed data. Bayesian inference allows making inferences
about both signiﬁcant and non-signiﬁcant effects by providing
the exact probability of their occurrence. The probabilities range
from with 0 (i.e., no evidence) to 1 (i.e., very strong evidence; see
Raftery, 1995). To calculate Bayesian probabilities we used the
method proposed by Wagenmakers (2007) and Masson (2011).
This method uses Bayesian information criteria (BIC), calculated
using a simple transformation of sum-of-squares values generated
by the standard ANOVA, to estimate Bayes factors and generate
p(H0|D) and p(H1|D), assuming a ‘‘unit information prior’’ (for fur-
ther details, see Kass and Wasserman (1995); see also Jarosz and
Wiley (2014)).
Due to a technical problem, one participant, assigned to the pla-
cebo group, did not ﬁll out the pre-intervention BAI questionnaire.
No other data were missing.3. Results
3.1. Randomization
Table 1 presents the participant characteristics by group (pro-
biotics versus placebo). No signiﬁcant group differences were
observed for age [t(38) = 0.76, p = 0.45], BMI [t(38) = 1.64,
p = 0.11], and gender distribution [v2 (1, N = 40) = 0.63, p = 0.43].
Table 2 gives a summary of pre- and post-intervention scores on
the LEIDS-R, BDI and BAI in the placebo and probiotics groups.
As anticipated on basis of participant selection, ANOVA per-
formed on the BDI–II total score revealed no main effect of time
[F(1,38) = .41, p = .52, p(H0|D) = .84], group [F(1,38) = 1.1, p = .31,
p(H0|D) = .78], nor a time by group interaction [F(1,38) = .41,
p = .52, p(H0|D) = .84]. Similarly, for the BAI scores no effect was
observed for time [F(1,37) = 2.30, p = .14, p(H0|D) = .66], group
[F(1,37) = 0.226, p = .64, p(H0|D) = .85], or for the interaction
between the two factors [F(1,37) = 0.064, p = .80, ps(H0|D) = .86].
Thus, the two groups of participants (placebo and probiotics) were
comparable in terms of depression and anxiety scores at baseline
and follow-up. Importantly, participants did not show any sign of
depression and anxiety in either sessions: only minimal/mild
scores were observed at both time points for the BDI–II (the mean
scores were 8.53, SD = 4.47, and 8.17, SD = 5.30, for the pre- and
post-intervention assessment, respectively) and BAI (the mean
scores were 11.77, SD = 7.32, and 10.55, SD = 7.20, the pre- and
post-intervention assessment, respectively; see also Table 2).3.2. Probiotic treatment and cognitive reactivity
ANOVAs revealed signiﬁcant time by group interactions for the
LEIDS-r total score [F(1,38) = 6.05, p = .019, gp2 = 0.137,
MSE = 40.468, p(H1|D) = .79], aggression [F(1,38) = 4.94, p = .032,
gp2 = .115, MSE = 4.255, p(H1|D) = .65], and rumination
[F(1,38) = 12.16, p = .001, gp2 = .242, MSE = 3.826, p(H1|D) = .98].
Tukey HSD post hoc tests performed to disentangle the interac-
tions revealed that participants who received a 4-week placebo
intervention showed comparable scores pre- versus post-interven-
tion (total score: p = .63, p(H0|D) = .70; aggression: p = .95,
p(H0|D) = .80; rumination: p = 1.0, p(H0|D) = .82; see Table 2). In
contrast, participants who received a 4-week probiotics interven-
tion scored signiﬁcantly lower at post-intervention compared to
the pre-intervention (total score: p < .001, p(H1|D) > .99; aggres-
sion: p = .004, p(H1|D) > .99; rumination: p < .001, p(H1|D) > .99;
see Table 2). Thus, our results show that the intake of multispecies
probiotics for a 4-week period signiﬁcantly reduced overall cogni-
tive reactivity to depression and in particular aggressive and
ruminative thoughts.4. Discussion
The aim of the current study was to investigate the effect of a
multispecies probiotic intervention on cognitive reactivity in
healthy individuals not currently diagnosed with a mood disorder.
As mentioned in the introduction, cognitive reactivity is an impor-
tant vulnerability marker of depression; the content and the type
of thoughts that are activated when an individual experiences
sad mood predicts whether the sad mood will be transient or will
persist, and predicts the development of clinical depression
(Abramson et al., 1989; Beck, 1967; Kovacs and Beck, 1978;
Haaga et al., 1991; Scher et al., 2005; Ingram et al., 2006). We
found that a 4-week multispecies probiotic intervention reduced
self-reported cognitive reactivity to sad mood, as indexed by the
LEIDS-r (van der Does and Williams, 2003; van der Does, 2005;
Kruijt et al., 2013). Further analyses showed that the strongest
Table 2
Mean pre- and post-intervention scores and standard error of the means (shown in
parentheses) on the LEIDS-r, BDI and BAI in the Placebo and Probiotics groups.
Asterisks indicate signiﬁcant treatment effect differences between pre- and post-
intervention assessments.
Pre-intervention Post-intervention
LEIDS-r
Aggression Placebo 8.80 (0.94) 8.45 (0.98)
Probiotics** 8.68 (0.94) 6.25 (0.98)
Control Placebo 7.65 (0.80) 6.70 (0.82)
Probiotics 7.25 (0.83) 5.80 (0.82)
Hopelessness Placebo 5.60 (0.85) 4.70 (0.74)
Probiotics 4.75 (0.85) 4.0 (0.74)
Risk aversion Placebo 9.50 (0.93) 9.25 (0.87)
Probiotics 10.00 (0.93) 7.95 (0.87)
Rumination Placebo 11.75 (0.90) 11.85 (0.93)
Probiotics*** 11.20 (0.90) 8.25 (0.93)
Acceptance Placebo 1.40 (0.34) 1.35 (0.37)
Probiotics 0.90 (0.34) 1.10 (0.37)
Total Placebo 44.70 (3.24) 42.30 (3.51)
Probiotics*** 42.75 (3.24) 33.35 (3.51)
BDI Placebo 9.10 (1.00) 9.10 (1.19)
Probiotics 7.90 (1.00) 7.25 (1.19)
BAI Placebo 12.21 (1.70) 11.21 (1.69)
Probiotics 11.35 (1.66) 9.95 (1.65)
⁄ p < .05
** p < .01.
*** p < .001.
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subscales, indicating that in the probiotics supplementation condi-
tion participants perceived themselves to be less distracted by
aggressive and ruminative thoughts when in a sad mood.
Notably, studies have shown that the tendency to engage in
ruminative thoughts is sufﬁcient to turn mood ﬂuctuations into
depressive episodes, and that individuals who typically respond
to low mood by ruminating about possible causes and conse-
quences of their state have more difﬁculties in recovering from
depression (Nolen-Hoeksema et al., 1993; Kuehner and Weber,
1999; Nolen-Hoeksema, 2000; Spasojevic and Alloy, 2001;
Moulds et al., 2008). Further, the activation of aggressive thoughts
has been associated with suicidal ideation and attempts (Oquendo
et al., 2006; Mann et al., 2008). In sum, the present results indicate,
for the ﬁrst time, that probiotics intervention can inﬂuence cogni-
tive mechanisms that are known to determine vulnerability to
mood disorders.
The present sample consisted of healthy individuals with mini-
mal to mild baseline scores on both the BAI and the BDI, and it is
not surprising therefore that the beneﬁcial effect of probiotics
intervention was selective for cognitive reactivity to depression
and not for self-report symptoms of depression or anxiety. This
observation is consistent with the ﬁndings reported by Benton
et al. (2006), who found that improvements in mood after probio-
tics administration only occurred in participants who showed ele-
vated symptoms of depression at the baseline. Importantly, the
selection of a nonclinical sample of participants provided the
opportunity to test speciﬁcally the possible beneﬁcial effects of
probiotics intervention on cognitive reactivity, i.e., not confounded
by ongoing depressive symptomatology. Further longitudinal stud-
ies in high-risk or clinical groups are necessary to conﬁrm poten-
tially clinically relevant effects. Given that the transition from
persistent changes in mood to the development of a depressive
episode can be months or longer, such studies may need to extend
past the current 4-week period.
While the present study did not set out to test speciﬁc biological
mechanisms that could underlie possible beneﬁcial cognitive
effects, the extant literature does allow for a number of hypotheses
testable in future studies. For example, it has been proposed thatintestinal microbiota increase plasma tryptophan levels, and
hereby potentially facilitate serotonin turnover in the brain
(Desbonnet et al., 2008, 2010). Interestingly, cognitive reactivity
to sad mood has been associated with serotonin concentrations,
with higher scores correlating with lower serotonin levels (Booij
and Van der Does, 2007; Wells et al., 2010; see also Firk and
Markus, 2009). However, other pathways are plausible as well.
For instance, it has been proposed that an increased intestinal
permeability can induce depressive symptoms (Ait-Belgnaoui
et al., 2012), possibly by endotoxin activated inﬂammatory path-
ways or via direct activation of glial and neural cells that carry
Toll-like receptors and are hereby responsive to a wide range of
microbial products (McCusker and Kelley, 2013). Given that certain
probiotics have been found to improve the epithelial barrier func-
tion and hereby decrease permeability (Van Hemert et al., 2013),
this mechanism might account for the beneﬁcial effects of probio-
tics on cognitive reactivity. Follow-up probiotics studies could
explore this possibility, for example by using the lactulose/manni-
tol ratio in urine to evaluate intestinal permeability (Teixeira et al.,
2014). Animal studies have further suggested that gut-to-brain sig-
nals are transmitted via the vagus nerve (Ter Horst and Postema,
1997; Tillisch et al., 2013). For example, a study in mice has shown
that the supplementation of probiotics has a beneﬁcial effect on
anxious and depressive behavior, but only with an intact vagus
nerve (Bravo et al., 2011). In humans the vagus nerve reaches,
via the locus coeruleus and the raphe nuclei (the principal sources
of serotonin released in the brain), the anterior cingulate cortex
(ACC) and the prefrontal cortex (PFC; Thayer and Lane, 2007), in
particular the mPFC (Mayer et al., 2006) – i.e., one of the brain
regions associated with the processing of affective and social infor-
mation (Adolphs, 2001). Stimulation of the vagus nerve has already
been described as a successful method to treat patients suffering
from depression (Nemeroff et al., 2006). Interestingly, Tillisch
and colleagues (2013) have found that 4-week intake of a fer-
mented probiotic milk product by healthy women was associated
with altered activity of brain regions (e.g., primary interoceptive
and somatosensory cortices, and precuneus) that control central
processing of emotion and sensation. Therefore, it would be of
interest to explore whether the treatment of depressive disorders
would further beneﬁt by combining probiotic supplementation
with stimulation of the vagus nerve.
The present study has a few limitations that deserve discussion.
First, we did not include dietary measures and did not control for
consumption of other probiotic products or fermented foods (e.g.,
yogurt). Hence we cannot exclude that the consumption of probio-
tics was accompanied by spontaneous dietary changes that may
have indirectly accounted for the effect. Second, compliance was
facilitated by text message reminders, but not further conﬁrmed
e.g., by stool bacterial analysis. However, prior studies which used
partly the same bacterial strains have shown presence of the
strains in stool samples of healthy volunteers (Koning et al.,
2008). A third limitation of the present study is that it tested a pre-
dominantly female sample, and generalizability to males is uncer-
tain therefore.’’
Finally, it is worth noting that our assessment only relied on
self-reported cognitive reactivity that, although established as a
psychometrically reliable index of cognitive reactivity and found
to be predictive of the development of depressive symptoms and
depressive disorder (van der Does, 2005; Kruijt et al., 2013), would
be considered to provide only indirect information on actual cogni-
tive reactivity at times of low mood. Future studies may therefore
expand these observations by experimentally inducing negative
mood and/or by including ambulatory measurements, e.g., using
experience sampling techniques, to evaluate possible beneﬁcial
effects of probiotics.
L. Steenbergen et al. / Brain, Behavior, and Immunity 48 (2015) 258–264 263To conclude, the present study demonstrated, for the ﬁrst time,
that a 4-week multispecies probiotic intervention has a positive
effect on cognitive reactivity to naturally occurring changes in
sad mood in healthy individuals not currently diagnosed with a
depressive disorder. More speciﬁcally, the probiotic intervention
reduced aggressive and ruminative thoughts in response to sad
mood. These ﬁndings provide information on a cognitive mecha-
nism that may be responsible for the positive mood effects of pro-
biotic supplementation (Benton et al., 2006; Rao et al., 2009;
Messaoudi et al., 2011; Logan and Katzman, 2005; Tillisch, 2014).
Future studies should investigate the neurobiological underpin-
nings of these observed effects and test the applicability of the cur-
rent ﬁndings to high-risk and clinical populations.Conﬂict of interest
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